How Peptide Medications Are Dosed, and Why Titration Matters

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient sat across from me a few weeks ago, genuinely frustrated. She'd been on a weekly peptide medication for six weeks, felt a little queasy every Thursday afternoon, and the scale hadn't moved the way she'd hoped. Her question was completely fair, and I get some version of it almost every week: if a bigger dose works better, why am I still crawling up the ladder one rung at a time?

It's one of the most common sources of confusion I run into at Magnolia Functional Wellness. People hear "starting dose" and mentally file it under "the real treatment hasn't begun yet." That's not what's happening. The starting dose is treatment. The slow climb is treatment. And the reason we do it that way has nothing to do with caution for caution's sake.

So let's talk about how these medications are actually dosed, what titration is really for, and why the number on your pen matters less than most people assume.

A Peptide Dose Isn't Like an Aspirin Dose

When you take ibuprofen, the relationship is fairly intuitive. More drug, more effect, shorter duration. Peptides don't behave that way, and understanding why makes the rest of this make sense.

Peptides are signaling molecules. They're short chains of amino acids that bind to specific receptors and tell cells to do something. A GLP-1 receptor agonist like semaglutide isn't suppressing appetite by brute chemical force. It's binding receptors in the hypothalamus, the brainstem, the gut, and the pancreas, and shifting how those systems talk to each other. That's a conversation, not a hammer.

Two practical consequences follow. First, these medications take a long time to reach steady state. Semaglutide has a half-life of roughly a week, which means it takes something like four to five weeks at any given dose before blood levels actually plateau. If you increase the dose at week two because nothing seems to be happening, you never actually found out what that dose could do. You just stacked a new one on top of an incomplete answer.

Second, the receptor systems adapt. This is the part that surprises people. The nausea, the early fullness, the occasional reflux, those tend to fade with continued exposure at the same dose. The appetite effect largely doesn't. So time spent at a lower dose isn't wasted time. It's the body building tolerance to the parts you don't want while holding onto the parts you do.

That asymmetry is the entire logic of titration. We're not slowly sneaking up on efficacy. We're letting side effects burn off before we ask the system for more.

Why We Start Low, and What Happens When We Don't

The side effects of GLP-1 receptor agonists are overwhelmingly gastrointestinal. Nausea leads the list, followed by constipation, diarrhea, reflux, and a sense of fullness that arrives two bites into dinner. Most of it is mild to moderate. Most of it is temporary. Almost all of it is dose-related and escalation-rate-related.

Here's what I've seen consistently in practice: patients who tolerate these medications poorly are very often patients who moved up too fast. Sometimes that's a prescriber pushing a schedule. Sometimes it's the patient, impatient and self-escalating. Either way, the outcome tends to be the same. Bad week, worse week, then they stop taking it altogether.

That last part is what I actually worry about. The failure mode of aggressive titration isn't usually a dangerous side effect. It's abandonment. A medication that works beautifully is worth nothing if you quit it in week five because you spent every weekend on the couch feeling awful. The slow schedule exists to keep you in the game.

There's also a body composition argument that doesn't get enough attention. Very rapid weight loss, driven by a dose that crushes appetite faster than your habits can adjust, tends to take more lean mass with it. If you're barely eating because food is unappealing, you're probably not hitting your protein target either. I'd rather see someone lose steadily at a moderate dose while lifting weights and eating properly than drop fast on a high dose and give back muscle they'll spend years trying to rebuild.

What the Trials Actually Did

This isn't a matter of clinical preference. The escalation schedules came out of the trial protocols, and the trials are worth knowing about.

The STEP 1 trial, published in the New England Journal of Medicine in 2021 by Wilding and colleagues, ran 68 weeks in nearly 2,000 adults with overweight or obesity. Participants didn't start at the target dose of 2.4 mg weekly. They spent sixteen weeks climbing to it, in defined steps. Gastrointestinal events were the most commonly reported adverse effects, and they were typically transient and mild to moderate. That sixteen-week ramp was a design decision, not an afterthought.

The dose-ranging work underneath it is arguably more instructive. A phase 2 trial published in The Lancet in 2018 by O'Neil and colleagues compared several semaglutide dose levels against liraglutide and placebo. It also did something clever: at the highest dose studied, it included both a standard escalation arm and a slower escalation arm. In other words, the researchers weren't just asking how much. They were asking how fast, and treating the answer as a real scientific question rather than an administrative detail.

On the tirzepatide side, the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues tested 5 mg, 10 mg, and 15 mg weekly over 72 weeks. Weight loss was dose-dependent, which is exactly what you'd expect. But note the structure again: roughly twenty weeks of escalation before anyone sat at their assigned maintenance dose. Nobody started at 15 mg.

And then there's the question of what happens when you stop. The STEP 4 trial, published in JAMA in 2021 by Rubino and colleagues, took patients through a twenty-week run-in to 2.4 mg, then randomized them to continue or switch to placebo. The group that continued kept losing. The group that switched regained. That finding reframes the whole conversation about dosing. The dose isn't temporary scaffolding you climb and then kick away. For most people it's an ongoing therapy, which is one more reason the dose you land on needs to be one you can actually live with.

A note on terminology, since it comes up constantly: Ozempic and Wegovy are FDA-approved products. Semaglutide is the drug substance they're built on. Mounjaro and Zepbound are FDA-approved products built on tirzepatide. Those trials studied those branded products under their approved dosing schedules, and that's the context the numbers above belong to.

Higher Isn't Automatically Better

Somewhere along the way, the maximum dose became a finish line in the public imagination. I'd like to retire that idea.

The goal is the lowest dose that gets you the result you want. That's it. If a patient is losing weight at a healthy clip, feels good, is eating enough protein, and is holding onto strength, there is no clinical reason to push them higher just because the pen goes higher. Escalating into side effects you didn't need to have isn't ambition. It's a mistake.

In practice, I'm watching a handful of things when I decide whether to move up, hold, or step back down:

• Rate of loss. Somewhere around half a percent to one percent of body weight per week is a reasonable target for most people. Faster than that consistently, and I start asking harder questions about intake and lean mass.
• Tolerability. Not just "any nausea," but whether it's interfering with eating enough, hydrating enough, or living normally.
• Protein and training. If someone isn't eating enough protein or isn't doing resistance work, raising the dose usually makes that problem worse, not better.
• Labs and clinical signals. Kidney function, glucose, lipids, and anything that suggests we should slow down rather than accelerate.
• What's happening in their life. A patient with a wedding, a work trip, or a rough stretch at home is usually not a patient who should be starting a new dose that week.

Plenty of my patients do beautifully and finish their course at a middle dose. They never touch the top of the range. That's not an incomplete treatment. That's a well-matched one.

What Titration Actually Looks Like in Our Southlake Practice

When someone starts peptide medication therapy with us, the first month is mostly about establishing a baseline and teaching. Injection technique, storage, which day of the week to inject and why consistency helps, what normal side effects feel like and what isn't normal.

Then we check in. Every month, at minimum. We look at the weight trend rather than any single reading, because weight is noisy and a bad Tuesday morning means nothing. We go through symptoms specifically: when does the nausea hit relative to the injection, is it worse with certain foods, how are the bowels, any right upper quadrant pain that might point at the gallbladder. We review protein intake honestly. We review what training looks like.

Only then do we talk about the dose.

And here's a Texas-specific one that I bring up more than you'd think: hydration. From May through September around here, people are already running a fluid deficit just from existing outdoors. Add a medication that reduces your appetite and therefore your incidental fluid intake from food, add some nausea that makes you not want to drink, and you've got a recipe for headaches, fatigue, constipation, and lightheadedness that gets blamed on the medication when it's really volume depletion. If a patient tells me they feel terrible in August, the first thing I ask about is water, not milligrams.

Sometimes we hold a dose for two months instead of one. Sometimes we step back down a level and re-approach. Sometimes we stay put indefinitely because the person is exactly where they want to be. Those are all normal outcomes, and none of them represent a failure of the protocol. The protocol was always meant to be individualized, and medically supervised dosing is the entire point of doing this with a physician rather than off a website.

The Takeaway

Titration isn't a hurdle between you and the real medication. It's how the medication is supposed to be used. The schedule exists because side effects fade with time at a given dose while the therapeutic effect largely persists, and because the fastest route to the highest number is also the fastest route to quitting.

If you're on one of these medications and feeling stuck at a lower dose, the question worth asking your physician isn't "when do I go up." It's "is this dose doing what we need it to do." Sometimes the answer is yes, and you stay. Sometimes it's not yet, and you wait out the steady state. Sometimes it's no, and you move.

That's a conversation, and it's one worth having with someone who's actually tracking your labs, your body composition, and your life. At Magnolia Functional Wellness here in Southlake, that conversation happens monthly, and the dose follows the patient rather than the other way around.